natgillin/translations-raw huggingface dataset:
For preparing compounds of formula (Ia), where R1 and R2 are as defined above, R3 is as defined for a compound of formula I, R4 is amino and m is 1. 
A. Za pripravu spojeva formule (Ia), gdje su R,; i R, definirani kao gore, R; je definiran kao za spoj formule I, Ru je amino imje 1.
Alternatively, compound of formula (III) wherein R3 represents a hydrogen atom may be halogenated in order to give compounds of formula (III) wherein R3 is a halogen atom such as a bromine atom or a chlorine atom. 
Alternativno se spoj formule (1Il), gdje R3 predstavlja atom vodika, može halogenirani kako bi se dobilo spojeve formule (III), gdje R3 je atom halogena, poput a atom broma ili klora.
A process for preparing a feed, characterized in that among conventional feed ingredients and conventional feed additives and auxiliary agents is added, with mixing, a fatty acid mixture in which the content of saturated fatty acids is more than 90 % and the amount of the fatty acid mixture in the feed is 1-10% by weight, and wherein the fatty acid mixture contains the following fatty acids, in %: 
Postupak pripreme životinjske hrane, naznačeno time da se među konvencionalne sastojke životinjske hrane i konvencionalne aditive životinjske hrane te pomoćna sredstva dodaje, miješanjem, mješavina masnih kiselina u kojoj je udio zasićenih masnih kiselina veći od 90% i iznos mješavine masnih kiselina u životnjskoj hrani od 1 do 10% težine, te naznačeno time da mješavina masnih kiselina sadrži sljedeće masne kiseline u %:
The cooking aid of claim 1, wherein at least one of the first oil or the second oil is selected from the group consisting of sunflower oil, rape seed oil, cotton seed oil, peanut oil, soya oil, olive oil, palm oil, coconut oil, palm kernel oil, and mixtures thereof. 
Kuhinjsko pomagalo u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2, naznačeno time što se ulje bira iz skupine koju čine suncokretovo ulje, repičino ulje, ulje pamukovog sjemena, kikirikijevo ulje, sojino ulje, maslinovo ulje, palmino ulje, kokosovo ulje, te ulje palminih koštica.
Preferably the polypeptide analog of the SP-C protein is represented by the general formula (Ia) (SEQ ID NO: 13) in which e and n are 0, and g is 1: 
CWLCRALIKRIQAMIPKGGRMLPQLVCRLVLRCS (Ila) Rekonstituirani surfakant prema patentnom zahtjevu 5, naznačen time da je analog prirodnog surfakanta proteina SP-C predstavljen općom formulom (Ia)
The method of claim 13 further comprising administering, concurrently or sequentially, a therapeutically effective amount of at least one additional therapeutic agent selected from the group consisting of an antidiabetic agent, an anti-obesity agent, a anti-hypertensive agent, an anti-atherosclerotic agent and a lipid-lowering agent. A method for treating type II diabetes comprising administering a therapeutically effective amount of a compound of formula I 
Primjena prema patentnom zahtjevu 13, naznačena time što se i spoj formule I kao i najmanje jedno dodatno terapeutsko sredstvo izabrano iz grupe koju čine antidijabetično sredstvo, sredstvo protiv debljine, anti-hipertenzivno sredstvo, anti-arterosklerotsko sredstvo i sredstvo za snižavanje nivoa lipida, koriste u proizvodnji lijeka u obliku farmaceutske kombinacije za istovremenu ili uzastopnu primjenu navedenog spoja formule I i navedenog najmanje jednog dodatnog terapeutskog sredstva.
The stripping composition of claim 1, wherein the at least one high-boiling co-solvent is diethylene glycol butylether. 
Sastav za skidanje u skladu s bilo kojim od prethodnih zahtjeva, naznačen time da je najmanje jedno suotapalo visokog vrelišta dietilen glikol butileter.
A combination according to claim 5 wherein the anti-inflammatory agent is a corticosteroid. 
Kombinacija u skladu s patentnim zahtjevom 5, naznačen time što je protuupalno sredstvo kortikosteroid.
quantized transformation coefficients of at least one transformation unit generated by performing inter prediction for at least one prediction unit in the coding unit to generate a predictor and performing transformation and quantization based on the predictor and the image; 
Uređaj (500, 1500) za dekodiranje slike, te uređaj sadrži: entropijski dekoder (520, 1510) koji provodi entropijsko dekodiranje za dobivanje kvantiziranih transformacijskih koeficijenata najmanje jedne transformacijske jedinice (870) u kodirajućoj jedinici (810);
The solid oral extended release pharmaceutical dosage form of any one of claims 1 to 5, wherein the extended release matrix formulation after having been stored at 25 °C and 60 % relative humidity (RH) for at least 1 month contains an amount of the at least one active agent in % (by wt) relative to the label claim of the active agent for the extended release matrix formulation that deviates no more than about 10 % points from the corresponding amount of active agent in % (by wt) relative to the label claim of the active agent for the extended release matrix formulation of a reference formulation prior to storage. 
Farmaceutski oblik doziranja s produljenim otpuštanjem u krutom obliku prema zahtjevu 1 ili 2, naznačen time da formulacija matrice s produljenim otpuštanjem nakon što je bila skladištena pri 25 *C€ i 60% relativne vlažnosti zraka (RH) barem 1 mjesec sadrži količinu od oko jednog aktivnog agensa u % (težinski udio) vezano uz deklaracijski zahtjev aktivnog agensa za formulaciju matrice s produljenim otpuštanjem koja odstupa ne više od oko 10 % točaka u odnosu na odgovarajuću količinu aktivnog agensa gledano u % (težinski udio) vezano uz deklaracijski zahtjev aktivnog agensa za formulaciju matrice s produljenim otpuštanjem prema referentnoj formulaciji prije skladištenja.
for each of at least some of a plurality of ovens carried by each one of the plurality of vehicles, determines at least one of a respective cooking temperature or cooking time to cook a respective content of the oven, based at least in part an estimated transit time for the respective vehicle to the respective one of the destinations to which the respective content of the oven is to be delivered; 
Prenosivi sustav za kuhanje i dostavu prema zahtjevu 1, naznačen time, da najmanje jedna upravljačka jedinica (102, 118) zaustavlja kuhanje sadržaja u štednjaku (210), kada se postigne zadano vrijeme kuhanja za postavljene temperature na kojima je određeni štednjak radio za vrijeme barem dijela putovanja vozila (240), na temelju dinamički ažuriranog predviđenog vremena putovanja do dostavnog odredišta (304) za sadržine određenog štednjaka.
is a hydrogen atom, an optionally substituted C1-6 alkyl group, an optionally substituted C3-8 cycloalkyl group, an optionally substituted C3-8 cycloalkyl-C1-6 alkyl group, an optionally substituted aryl group, an optionally substituted ar-C1-6 alkyl group, an optionally substituted acyl group, an optionally substituted heterocyclic group or an optionally substituted heterocyclic C1-6 alkyl group, 
je atom vodika, po izboru supstituirana C1-6 alkilna skupina, po izboru supstituirana C3-8 cikloalkilna skupina, po izboru supstituirana C3-8 cikloalkil-C1-6 alkilna skupina, po izboru supstituirana arilna skupina, po izboru supstituirana ar-C1-6 alkilna skupina, po izboru supstituirana acilna skupina, po izboru supstituirana heterociklička skupina ili po izboru supstituirana heterociklička C1-6 alkilna skupina, pod uvjetom da kada G1 je CH, G2 je CH, G3 je CH, R1 je atom klora, atom broma, atom joda, C1-4 alkilna skupina, trifluorometilna skupina, dibutilamino skupina, metoksi skupina ili supstituirana feniloksi skupina, R2 je -COOH i R3 je atom vodika, tada je R4 skupina kako je predstavljeno općim formulama (3-1a) do (3-3a):
The second waterproofing layer 19 for the internal face 17 of the hollow structure 16 is constituted by one or more additional sheets of EPDM or the like, as described for the first waterproofing layer 15 . 
Osnova sukladno jednom ili više prethodnih zahtjeva, naznačena time što je navedeni drugi vodootporni sloj (19) unutarnjeg dijela (17) šuplje strukture (16) načinjen od jednog ili više listova EPDM ili sličnih.
is phenyl or pyridyl, which is para-substituted by Hal and/or meta-substituted by Hal or LA, and pharmaceutically acceptable salts, solvates, or solvates of salts, thereof. 
R> je fenil ili piridil, koji je para-supstituiran s Hal i/ili meta-supstituiran s Hal ili LA, i njihove farmaceutski prihvatljive soli, solvati ili solvati soli.
Diffuser as claimed in the preceding claims, characterised in that it includes means for connection to a control unit to allow programming of the operation of the device. 
Raspršivač prema prethodnim zahtjevima, naznačen time da sadrži sredstva za priključenje na upravljačku jedinicu koja omogućava programiranje rada uređaja.
The compound is a macrocyclic triene antibiotic that possesses antifungal activity, particularly against Candida albicans, both in vitro and in vivo. 
Spoj je makrociklilčki trienski antibiotik koji posjeduje antifungalnu aktivnost, naročito protiv organizma Candida albicans, i to jednako in vitro i in vivo.
A compound according to any of claims 1 to 7 or a composition according to claims 8 or 9 for use in the treatment or prevention of a disorder or disease associated with a RyR that regulates calcium channel functioning in cells. The compound of claim 10, wherein the disorder or disease is selected from the group consisting of cardiac disorders and diseases, skeletal muscular disorders and diseases, cognitive disorders and diseases, malignant hyperthermia, diabetes, and sudden infant death syndrome. 
C 2 (536), za liječenje ili prevenciju poremećaja ili bolesti povezanih s RyR koji regulira funkciju kalcijevih kanala u stanicama, ili u proizvodnji lijeka za takvo liječenje ili prevenciju, pri čemu je poremećaj ili bolest povezana s RyR izabrana iz grupe koju čine poremećaji i bolesti skeletnih mišića, kognitivni poremećaji 1 bolesti, maligna hipertermija, dijabetes i sindrom iznenadne smrti novorođenčeta.
Preferably the base TPE is a styrene-ethylene/butylene-styrene (“SEBS”) thermoplastic elastomer. 
Poželjno je da je osnovni TPE stiren-etilen/butilen-stiren ("SEBS") termoplastični elastomer.
and wherein said binding protein comprises a light chain polypeptide having the sequence of SEQ ID NO. 
i pri čemu navedeni vezni protein obuhvaća polipeptid lakog lanca i ima slijed of SEQ ID NO.
The details of the invention, its objects and advantages are explained hereunder in greater detail in relation to non-limiting exemplary illustrations. 
Detalji izuma, njegovi ciljevi 1 prednosti objašnjeni su u daljnjem tekstu detaljnije u odnosu na neograničavajuće ilustracije primjera.
The pharmaceutical composition of Claim 6, further comprising a secondary therapeutic agent selected from anti-Alzheimer's agents, anticonvulsants, antidepressants, anti-Parkinson's agents, dual serotonin-norepinephrine reuptake inhibitors, non-steroidal anti-inflammatory agents, norepinephrine reuptake inhibitors, opioid agonists, opioid antagonists, selective serotonin reuptake inhibitors, sodium channel blockers, sympatholytics, and combinations thereof. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 25, naznačen time, da je nazočno drugo terapijsko sredstvo i da je odabrano od sredstava protiv Alzheimerove bolesti, antikonvulzanata, antidepresiva, sredstava protiv Parkinsonove bolesti, dvojnih serotonin-norepinefrinskih povratnih inhibitora, nesteroidnih protu-upalnih sredstava, norepinefrinskih povratnih inhibitora, opioidnih agonista, opioidnih antagonista, selektivnih serotonininskih povratnih inhibitora, blokatora natrijevih kanala, simpatolitika i njihovih kombinacija.
The method as claimed in claimed 1, wherein, a procedure of corrosion resistance (36) is subsequently proceeding after said procedure of thread formation (34) in order to coat with a rust-resistant layer (46) on an outer surface of said integral fastener (4) for corrosion protection. 
Postupak prema zahtjevu 1, naznačen time što postupak dodavanja otpornosti na koroziju (36) slijedi nakon spomenutog postupka oblikovanja navoja (34), pri čemu se dodaje sloj otporan na koroziju (46) na vanjsku površinu cjelovitog vijka (4) radi zaštite od korozije. t>&
The one or more nucleic acids of claim 1, wherein the anti-NR10 antibody is an NR10-binding antibody fragment. 
Anti-NR10 protutijelo u skladu s patentnim zahtjevom 1 ili 2, naznačeno time, da je protutijelo humanizirano.
Another embodiment of the present invention is a combination of an M3 antagonist which is (3R)-1-phenethyl-3-(9H-xanthene-9-carbonyloxy)-1-azoniabicyclo[2.2.2]octane bromide, with a LABA selected from formoterol, salmeterol, GSK-597901, GSK-159797, KUL-1248, TA-2005 and QAB-149. 
Sljedeće utjelovljenje predmetnog izuma je kombinacija M3 antagonista, koji je spoj 3(R)-(2-hidroksi-2,2-ditien-2- ilacetoksi)-1-(3-fenoksipropil)-1-azoniabiciklo[2.2.2]oktan bromid s kortikosteroidom odabranim između sljedećeg: budesonid, beklometazon dipropionat, mometazon furoat, ciklesonid 1 flutikazon propionat.
The term DYSLIPIDEMIA is intended herein to encompass disorders comprising any one of elevated level of plasma free fatty acids, elevated level of plasma cholesterol, elevated level of LDL-cholesterol, reduced level of HDL-cholesterol, and elevated level of plasma triglycerides. 
Izraz DISLIPIDEMIJA namjerava obuhvatiti poremećaje koji sadrže bilo koji povišeni nivo plazminih slobodnih masnih kiselina, povišeni nivo holesterola u plazmi, povišeni nivo LDL-holesterola, sniženi nivo HDL-holesterola i povišeni nivo triglicerida plazme.
A said pharmaceutical composition can be prepared by mixing and processing an M3 antagonist of the invention, a corticosteroid and optionally other additives and/or carriers by methods known per se. 
Navedeni farmaceutski pripravak može se pripravljati miješanjem i obradom M3 antagonista sukladno predmetnom izumu, P2-agonista i po izboru drugih pomoćnih tvari i/ili nosača postupcima koji su poznati per se.
The process of claim 29, wherein said second solvent is selected the group consisting of halogenated solvents, aromatic solvents and nitrogen-containing solvents. 
Postupak u skladu s patentnim zahtjevom 29, naznačen time što navedeno drugo otapalo se bira iz skupine koju čine halogenirana otapala, aromatska otapala i otapala koja sadrže dušik.
Method 1 (for compounds of formula IA) Alkylating an amine of formula III with an alkylating derivative of formula II: 
5 Metoda 1 (za spojeve formule IA). Alkilacija amina formule III s alkilacijskim derivatom formule II
Capsule according to claim 1, 2 or 3, wherein the inner space of the capsule has a volume of approximately 10-14 ml, preferably 11.5 - 12.5 ml, more preferably approximately 11.8 ml. 
Kapsula prema zahtjevu 1, 2 ili 3, naznačena time, da unutrašnjost kapsule ima volumen od otprilike 10-14 ml, poželjno 11,5-12,5 ml, još bolje od otprilike 11,8 ml.
Keep product out of the reach of children. 
Datum objave europske prijave patenta:
A process for manufacturing a stable pharmaceutical tablet comprising rosuvastatin, according according to claim 1-7, consisting of: compressing the powder blend coating the compressed core with a film free of iron oxides, to a weight gain of 2 -10%, particularly, 3 - 4%. 
Postupak proizvodnje stabilne farmaceutske tablete koja sadrži rosuvastatin, u skladu s patentnim zahtjevom 1-6, naznačen time što se sastoji u: a. - komprimiranju praškaste smjese b. - oblaganju komprimirane jezgre filmom koji ne sadrži željezne okside, do dobitka na težini od 2-10%, osobito, 3-4%.
WO 01/60805 (SmithKline Beecham plc), discloses a novel class of pyrimidinone compounds, inter alia those substituted at Nl and containing a sulphur atom. 
WO 01/60805 (SmithKline Beecham ple), otkriva novu klasu pirimidinonskih spojeva, među ostalim onih supstituiranih na N1i koji sadržavaju atom sumpora.
Disclosed are those compounds wherein R4 is phenyl substituted with one to three R41 substituents independently selected from the group consisting of (C1-3)alkyl, (C1-3)alkoxy, phenyl(C1-3)alkoxy, hydroxy, C1-6alkylaminocarbonyl, and aminocarbonyl; provided that no more than one R41 substitutent is aminocarbonyl, C1-6alkylaminocarbonyl, hydroxy, or a phenyl-containing substituent. 
Spoj prema zahtjevu 1 naznačen time da R" je fenil supstituiran sa jednim do tri R"' supstituenta nezavisno izabrana iz skupine koju čine (Crs)alkil, (Crg)alkoksi, feni(C,.)alkoksi, hidroksi, C,salkilaminokarbonil i aminokarbonil; uz uvjet da ne više od jedan R"' supstituent je aminokarbonil, C, galkilaminokarbonil, hidroksi ili supstituent koji sadrži fenil.
1 or 3 and/or the light chain variable region shown in SEQ ID NO. 
1 ili 3 1 varijabilno područje lakog lanca prikazano u SEQ ID NO.
The computer implemented method of claim 1, further comprising initializing, by the computing device, the debugging process including creating a debugging process based upon, at least in part, the packed portable executable file. The computer implemented method of claim 1, further comprising realigning, by the computing device, the debugged portable executable file. 
Postupak kojeg provodi računalo u skladu s patentnim zahtjevom 1, naznačen time što dodatno uključuje pokretanje, od strane računalnog uređaja, postupka uklanjanja pogrešaka, uključujući pokretanje postupka uklanjanja pogrešaka na osnovi, u najmanju ruku djelomično, pakirane prijenosne izvršne datoteke.
detecting said sinusoidal current component and comparing it with the sinusoidal portion of the sent reference current, 
detektiranje navedene komponente sinusoidalne struje i njeno uspoređivanje sa sinusoidalnim udjelom uvedene referentne struje,
More preferably, the matrix is comprised of non-woven polyester and the support is comprised of a sheet of polypropylene mesh with substantially square mesh opening of about one square millimeter. 
Poželjnije, matrica se sastoji od ne-utkanih poliestera, a potpora se sastoji od plohe polipropilenske mreže s približno kvadratičastim otvorima od oko jednoga kvadratnog milimetra.
The method of claim 29, wherein said once-off shared keycode is unique over the duration of its validity period. 
Postupak u skladu s patentnim zahtjevom 29, naznačen time što je navedeni jedinstveni zajednički kodni ključ jedinstven tijekom trajanja njegovog roka valjanosti.
Addition of 1,4-diamino-benzene to the chloroimidate followed by reaction with the appropriate acid chloride gives the desired compounds, as shown in Scheme 2. 
Dodavanje 1,4-diamino-benzena ka klorimidatu, nakon čega slijedi reakcija s odgovarajućim kiselinskim kloridnom daje željene spojeve, kao što je prikazano na Shemi 2.
The isolated antibody of claim 2, wherein said antibody binds to the extracellular domain of a protein comprising the amino acid sequence of SEQ ID NO: 2 expressed by said cells and/or associated with the surface of said cells. The isolated antibody of claim 1, wherein said cells are cancer cells. 
ID BR: 2 eksprimiranog od strane spomenutih stanica i/ili vezanog sa površinom spomenutih stanica, poželjno vezivanjem spomenutog antitijela za izvanstanični domen proteina koji sadrži aminokiselinsku sekvencu sa SEK ID BR: 2 eksprimiranog od strane spomenutih stanica i/ili vezanog sa površinom spomenutih stanica.
A compound or salt according to claim 1 in which X is O and R3 is C1-C3 straight or branched alkyl optionally substituted by from 1 to 3 halogen atoms. 
Spoj ili sol u sklađu s patentnim zahtjevom 1, naznačen time što X je O, a Rz je Ci-C; nerazgranati ili razgranati alkil, izborno supstituiran s 1 do 3 atoma halogena.
The method of any one of the preceding claims, wherein a rodent portion of the chimeric human/rodent MHC II a polypeptide comprises transmembrane and cytoplasmic domains of an endogenous rodent MHC II a polypeptide and/or wherein a rodent portion of the chimeric human/rodent MHC II B polypeptide comprises transmembrane and cytoplasmic domains of an endogenous rodent MHC II B polypeptide. 
U glodavca iz zahtjeva 1. glodavački dio kimernog MHC II a. polipeptida čovjeka/glodavca sadrži transmembranske 1 citoplazmatske domene endogenog MHC II a. polipeptida glodavca i/ili glodavački dio kimernog MHC II BB polipeptida čovjeka/glodavca sadrži transmembranske i citoplazmatske domene endogenog MHC II f3 polipeptida glodavca.
The method of claim 11, wherein the avermectin compound is ivermectin in a concentration greater than about 0.05% (w/w). 
Uporaba prema jednom od zahtjeva 1 do 2, naznačena time da je navedeni spoj avermektina u koncentraciji većoj od oko 0.05% (tež./tež.).
A plug of Burley tobacco, about 100 mg was placed against the mouth end of the substrate. 
Čep od Burlev duhana, oko 100 mg, stavljen je naspram usnog kraja supstrata.
g/L to 1,000 g/L water-suspended microparticulate calcite mineral; 
100 g/1 do 1000 g/l mikropartikuliranog minerala kalcita suspendiranog u vodi;
In an even more preferred embodiment the beverage or foodstuff obtainable by the present method contains at least 0.5 mg/kg, preferably at least 1 mg/kg of a fructosazine selected from the group consisting of 2,5-deoxyfructosazine, 2,6-deoxyfructosazine, 2,5-fructosazine, 2,6-fructosazine and combinations thereof. 
U čak još poželjnijem ostvarenju, piće ili prehrambeni proizvod, koji se može dobiti sadašnjim postupkom, sadržava najmanje 0,5 mg/kg, poželjno najmanje 1 mg/kg fruktozazina odabranog iz skupine koju sačinjavaju 2,5-deoksifruktozazin, 2,6-deoksifruktozazin, 2,5-fruktozazin, 2,6-fruktozazin i njihove kombinacije.
substituted at 3-position or 4-position on the benzene ring of the matrix; wherein one end of atom N is connected with the matrix; 
H supstituiran na poziciji 3 ili 4 na benzenskom prstenu matrice; pri čemu je jedan kraj atoma N povezan sa matricom; n n ta a
Method for the treatment of a disease or pathological condition susceptible of amelioration by modulation of the adenosine A3 receptor, said method comprising administering to a subject in need thereof an effective amount of a compound according to claim 1, wherein the disease or pathological condition susceptible of amelioration by modulation of the adenosine A3 receptor is selected from the group consisting of: atherosclerosis; asthma; autoimmune diseases selected from rheumatoid arthritis and psoriasis, diseases of the gastrointestinal system selected from ulcerative colitis, Crohn's disease, and inflammatory bowel disease; and ophthalmologic diseases selected from glaucoma and uveitis. 
Spoj u skladu s patentnih zahtjeva 1 do 10, naznačen time što je namijenjen upotrebi u liječenju bolesti ili patološkog stanja kojeg se može ublažiti moduliranjem adenozinskog receptora A3, kojeg se bira iz skupine koju čine Alzheimerova bolest, Huntingtonova bolest, Parkinsonova bolest, ateroskleroza, astma, rak, akutna bubrežna insuficijencija, reumatoidni artritis, Crohnova bolest, kolitis, sindrom iritabilnih crijeva, glaukom, sindrom suhih očiju i uveitis.
is selected from the group consisting of hydrogen, alkyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heterocycle, heteroarylalkyl, and (NRCRD)sulfonyl; and RC and RD are independently selected from the group consisting of hydrogen and alkyl. 
RA i RB su neovisno odabrani iz skupine koja se sastoji od vodika, alkila i alkilkarbonila; i RC i RD su neovisno odabrani iz skupine koja se sastoji od vodika i alkila.
the human light chain comprises SEQ ID NO: 17. 
ljudski laki lanac sadrži SEQ ID NO: 14.
The sheath according to claim 1 or 2, where the cavities (3) have a substantially truncated cone shape, characterised in that the fibres are also distributed on a lateral surface (3a) and on a base surface(3b) of each truncated cone cavity (3). 
Obloga prema zahtjevu 1 ili 2, gdje šupljine (3) imaju u osnovi oblik krnjeg stošca, naznačena time da su vlakna također raspoređena na bočnoj površini (3) i na osnovnoj površini (3b) svake šupljine (3) krnjeg stošca.
Q- is independently selected from: 
je neovisno odabran od: